glp-1 receptor agonists energy fatigue effects 2025 Glucagon-like peptide-1 and muscle mass Extending Healthspan via GLP-1 Receptor
Description
Muta Y, Kobayashi K, Toyoda M, et al
This trial, ATTAIN-2, was a double-blind 72-week trial in 136 sites across 10 countries
Indicative studies include findings suggesting improved survival rates and reduced graft loss for kidney transplant recipients with diabetes using these agents
L.JiaoX.et al
GLP1 receptor agonistseffects beyond obesity and diabetes
